Joel Isaacson & Co’s Ginkgo Bioworks DNA Stock Holding History

Joel Isaacson & Co’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,203	Closed	-$89.5K	–	311
2023 Q2	$89.5K	Sell	1,203 -742	-38%	-$43.9K	0.01%	313
2023 Q1	$103K	Sell	1,945 -950	-33%	-$60.2K	0.01%	317
2022 Q4	$196K	Buy	+2,895	New	+$266K	0.02%	304

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Joel Isaacson & Co's DNA Position: Q3 2023 in Review

Joel Isaacson & Co sold out of Ginkgo Bioworks (DNA) in Q3 2023, closing a stake of 1,203 shares — an estimated $89.5K sold.

Joel Isaacson & Co first reported a position in DNA in Q4 2022 and held it in 3 quarters. The position peaked at $196K in Q4 2022. 348 funds tracked by Wall St. Rank hold DNA as of Q3 2023.

Joel Isaacson & Co reported no remaining Ginkgo Bioworks position as of Q3 2023 after selling out during the quarter.
Joel Isaacson & Co sold 1,203 Ginkgo Bioworks shares in Q3 2023, an estimated $89.5K.
Joel Isaacson & Co first reported a position in Ginkgo Bioworks in Q4 2022 and held it in 3 quarters.
Joel Isaacson & Co's Ginkgo Bioworks position peaked at $196K in Q4 2022.
348 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2023.

Based on Joel Isaacson & Co's 13F filing for Q3 2023, filed 24 Oct 2023.